Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort.
Akihito KawazoeNoboru YamamotoNaotoshi SugimotoHiasto KawakamiTakashi OshimaKensei YamaguchiKaori HinoMotohiro HiraoYukinori KurokawaTakeshi KawakamiMasahiro TsudaHiroki HaraShota KanameDaiko MatsuokaYohei OtakeKeisuke YasudaTakao TakaseShuya TakashimaTaro SembaKei MuroPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Promising antitumor activity was observed with E7389-LF in combination with nivolumab in patients with gastric cancer, and no new safety signals were observed, compared with either monotherapy.